Marc Goodman
Stock Analyst at Leerink Partners
(2.92)
# 1,670
Out of 5,072 analysts
94
Total ratings
56.58%
Success rate
27.73%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics | Initiates: Outperform | $30 | $12.99 | +130.95% | 1 | Nov 21, 2025 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $5 | $1.63 | +206.75% | 1 | Nov 17, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Market Perform | $19 | $21.40 | -13.55% | 3 | Oct 23, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Outperform | $34 | $16.53 | +105.69% | 1 | Oct 6, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $9.48 | +427.43% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $15.00 | -33.33% | 5 | May 7, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $150.98 | -0.65% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $4.19 | -76.13% | 3 | Dec 4, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $30.72 | +4.17% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $128.72 | -80.58% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $19.40 | +157.73% | 1 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $7.04 | +184.09% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $100 → $115 | $151.58 | -24.13% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $181.94 | +70.39% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $44.49 | +3.39% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $24.81 | -15.36% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $176.92 | +18.70% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.93 | +241.30% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $29.72 | -9.15% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.59 | +168.34% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $535.16 | -49.55% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $227.66 | -57.83% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $49.25 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $104.63 | -35.96% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $13.42 | +630.25% | 7 | Oct 5, 2017 |
MapLight Therapeutics
Nov 21, 2025
Initiates: Outperform
Price Target: $30
Current: $12.99
Upside: +130.95%
Ovid Therapeutics
Nov 17, 2025
Initiates: Outperform
Price Target: $5
Current: $1.63
Upside: +206.75%
Avadel Pharmaceuticals
Oct 23, 2025
Downgrades: Market Perform
Price Target: $19
Current: $21.40
Upside: -13.55%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $16.53
Upside: +105.69%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $9.48
Upside: +427.43%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $15.00
Upside: -33.33%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $150.98
Upside: -0.65%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $4.19
Upside: -76.13%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $30.72
Upside: +4.17%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $128.72
Upside: -80.58%
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $19.40
Upside: +157.73%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $7.04
Upside: +184.09%
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $151.58
Upside: -24.13%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $181.94
Upside: +70.39%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $44.49
Upside: +3.39%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $24.81
Upside: -15.36%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $176.92
Upside: +18.70%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.93
Upside: +241.30%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $29.72
Upside: -9.15%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.59
Upside: +168.34%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $535.16
Upside: -49.55%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $227.66
Upside: -57.83%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $49.25
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $104.63
Upside: -35.96%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $13.42
Upside: +630.25%